It is therefore of high clinical value to maximize the anti-tumor effects of HDAC3 inhibition in the broader population of DLBCL patients, in addition to the subset of cases harboring CREBBP mutations. Here, HDAC3 is linked to diffuse large B-cell lymphoma.